Clinical discontinuation does not erase a compound’s research value. CP-724714 entered Phase I as an oral HER2 inhibitor, but liver abnormalities ended development. Its kinase profile and toxicity mechanisms support two uses: probing HER2 signaling and studying drug-induced liver injury.
A quinazoline designed to spare EGFR
CP-724714 is a reversible, ATP-competitive quinazoline inhibitor. Biochemical assays reported an IC50 of 10 ± 3 nM for ErbB2, compared with 6400 ± 2100 nM for EGFR—approximately 640-fold selectivity. Selectivity exceeded 1000-fold against tested IR, IGF1R, PDGFR-beta, VEGFR2, Abl, Src, c-Met, JNK, CDK2, and CDK5.
Laboratories can source the compound through https://ebc.enamine.net/molecule-product/EBC-220082 for HER2-focused experiments rather than broad ErbB-family inhibition. Selectivity remains concentration- and assay-dependent, so suitable controls are still needed.
Why hepatotoxicity became a research use
Phase I testing identified reversible liver-function abnormalities, and later work examined their causes. CP-724714 entered human hepatocytes rapidly, partly through OATP1B1, while MDR1 and BCRP contributed to efflux. It inhibited the bile salt export pump at about 16 micromolar and MDR1 at about 28 micromolar. Human-hepatocyte imaging also implicated mitochondria in direct toxicity.
These findings support a mixed mechanism involving hepatocellular injury, intracellular accumulation, and impaired canalicular transport of bile constituents. The compound is therefore a documented case for evaluating transporter-mediated cholestasis and mitochondrial liability, not simply “HER2 inhibitor hepatotoxicity.”
What happens in HER2-driven cells
In HER2-amplified BT-474 breast cancer cells, CP-724714 reduced ErbB2 autophosphorylation, produced G1 arrest, and lowered the S-phase fraction. HER2 has no known direct ligand and frequently acts as the preferred dimerization partner for other ErbB receptors. However, overexpressed HER2 can sustain ligand-independent signaling, so the response should not be described as disruption of heterodimerization alone.
From target modulation to xenograft response
Oral dosing in FRE-ErbB2 xenografts reduced receptor phosphorylation dose-dependently, with an ED50 near 19 mg/kg. Treatment also induced apoptosis and inhibited tumor growth. In BT-474 and MDA-MB-453 xenografts, it produced dose-dependent growth inhibition; BT-474 tumors additionally showed reduced ERK and Akt phosphorylation. These results connect biochemical potency with target modulation and antitumor effects in vivo.
For target-validation studies, CP-724714 remains a useful HER2-selective reference, not proof of absolute specificity. Its value comes from biochemical, cellular, xenograft, clinical, and toxicology data within one compound.
